X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Phospholipid Drug Conjugates
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Cellectar
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration July 13, 2021
Details:
The collaboration focuses on combining IntoCell’s validated novel Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker chemistry with Cellectar’s validated novel targeting platform, phospholipid ethers (PLEs) to develop new PDCs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human Antibody-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 06, 2021
Details:
The agreement grants Pierre Fabre the worldwide exclusive rights to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax®-ABL library owned by Y-Biologics.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
